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Abstract
Background: The aim of this study is to compare the cost-effectiveness of screening with stool
DNA testing with that of screening with other tools (annual fecal occult blood testing, flexible
sigmoidoscopy every 5 years, and colonoscopy every 10 years) or not screening at all.
Methods: We developed a Markov model to evaluate the above screening strategies in the general
population 50 to 75 years of age in Taiwan. Sensitivity analyses were performed to assess the
influence of various parameters on the cost-effectiveness of screening. A third-party payer
perspective was adopted and the cost of $13,000 per life-year saved (which is roughly the per capita
GNP of Taiwan in 2003) was chosen as the ceiling ratio for assessing whether the program is cost-
effective.
Results: Stool DNA testing every three, five, and ten years can reduce colorectal cancer mortality
by 22%, 15%, and 9%, respectively. The associated incremental costs were $9,794, $9,335, and
$7,717, per life-year saved when compared with no screening. Stool DNA testing strategies were
the least cost-effective with the cost per stool DNA test, referral rate with diagnostic colonoscopy,
prevalence of large adenoma, and discount rate being the most influential parameters.
Conclusion: In countries with a low or intermediate incidence of colorectal cancer, stool DNA
testing is less cost-effective than the other currently recommended strategies for population-based
screening, particularly targeting at asymptomatic subjects.
Background
Because of the high incidence, long preclinical period, and
availability of treatment which gives a favorable prognosis
with early diagnosis, screening for colorectal cancer (CRC)
has been shown to lead to substantial mortality reduc-
tions in Western countries; 15–33% with fecal occult
blood testing (FOBT), 33% with flexible sigmoidoscopy
and 57% with colonoscopy [1-7]. The U.S. Multisociety
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Task Force on Colorectal Cancer has therefore recom-
mended multiple options for screening people at average
risk of CRC including annual FOBT, flexible sigmoidos-
copy every 5 years, and colonoscopy every 10 years [8].
Given this choice of effective screening tools, the deciding
factor amongst alternatives could be efficacy, performance
(sensitivity and specificity), acceptability, feasibility, com-
pliance, and clinical capacity. Colonoscopy, for example,
has been recommended as one of the screening options in
the USA because of high sensitivity and specificity [8].
However, in countries with a shortage of medical endo-
scopic manpower the resulting increased demand for
colonoscopy may render such a scheme unworkable. In
addition, the uptake of colonoscopy is likely to depend
upon local social and cultural issues.
Recently, a new method for detecting adenoma and inva-
sive CRC, known as stool DNA testing, has been suggested
as a potential screening tool [8,9]. It analyzes the DNA
contained in stools, through natural exfoliation, and
detects alterations. The sensitivity of stool DNA testing,
based on symptomatic cases, has been reported as
between 36% and 82% for advanced adenoma and
between 61% and 100% for invasive cancer, and the spe-
cificity has been estimated at between 89% and 100% in
clinical studies [10-15]. A recent large prospective study,
targeting average-risk, asymptomatic subjects aged 50
years or older, reported more conservative results when
using stool DNA testing as a screening tool; sensitivities of
15% and 52% respectively for adenoma and invasive can-
cer [16]. Nevertheless, stool DNA testing was found signif-
icantly better than the fecal occult blood test [16]. Since
the costs associated with stool DNA testing are considera-
ble the issue of whether the required expenditure could be
offset by future savings (brought about by a reduction in
the number of advanced cases needing treatment) must be
addressed before stool DNA testing, as a population-
based screening tool for average-risk, asymptomatic sub-
jects, can be introduced. This is particularly important for
countries with a low or intermediate, but nevertheless dra-
matically increasing, incidence of CRC.
In Taiwan for instance, CRC has been ranked as the fourth
most common cancer and accounted for 11% of cancer
cases and 12% of cancer deaths in 2000 [17]. The age-
adjusted incidence has increased by 50%, from 19.4 per
100,000 in 1995 to 28.3 per 100,000 in 2000, while the
associated mortality has increased from 11.3 to 12.7 per
100,000.
The aim of this study is therefore to perform a decision
analysis using a Markov model to compare the effective-
ness and cost of stool DNA testing with other conven-
tional screening strategies. The cost-effectiveness analysis
compares triennial, five-yearly, and ten-yearly stool DNA
testing (DNA3, DNA5, and DNA10), with no screening (No
Screening), annual FOBT (FOBT1), five-yearly flexible sig-
moidoscopy (SIGM5), and ten-yearly colonoscopy
(COLO10).
Methods
Model specification
We developed a Markov model by using DATA Version
3.5 (TreeAge Software) to consider several screening strat-
egies for CRC, including DNA3, DNA5, DNA10, FOBT1,
SIGM5, COLO10, and No Screening. Subjects at average-
risk of developing CRC were screened from age 50 years
until age 75 or death. For each Markov decision, all possi-
ble transition states radiated from the decision node with
1-year Markov cycles. Effectiveness was defined as addi-
tional life-years gained as a result of screening.
The disease natural history of CRC was simulated by a
nine-state Markov model (Figure 1) consisting of normal,
small adenoma (adenoma smaller than 1 cm in size),
large adenoma (adenoma larger than 1 cm in size), pre-
clinical early CRC (preclinical Dukes' stage A and B CRC),
preclinical late CRC (preclinical Dukes' stage C and D),
clinical early CRC, clinical late CRC, CRC death, and other
cause of death. Our model only focuses on modeling ade-
noma-carcinoma sequences without considering non-
polypoid CRC because information on the sensitivity and
specificity of the screening tool for detecting the non-
polypoid form is unclear. The progression from each state
to the next follows a Markov process that assumes that
transition depends only on the current state, i.e. the proc-
ess has no memory. The solid arrows represent the direct
transition between states, and the dotted ones the transi-
tion toward other cause of death. The transition rates are
denoted as λ1(t), λ2, ..., λ8, and μ(t) where, for example, λ2
is the annual transition rate from small to large adenoma,
and  μ(t) is the annual age-specific mortality rate from
other causes. Note that as the annual incidence rate of
small adenoma increases with age we allow it to vary with
time according to the Weibull distribution denoted as
λ1(t), i.e. annual incidence rate of small adenoma in sub-
jects aged t. The hazard function for the Weibull distribu-
tion is
λ1(t) = λ10γtγ-1
where λ10 and γ are the scale and shape parameters respec-
tively. We assume the other transition parameters, λ2-λ8,
are constant over time. The estimated transition rates are
shown in Table 1.
Following Cox and Miller [18], Duffy et al [19] and Chen
et al [20], the corresponding annual transition probabili-
ties from one state to another can be obtained by convert-BMC Cancer 2006, 6:136 http://www.biomedcentral.com/1471-2407/6/136
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ing the transition rates. The Markov model specifying the
transitions between states in Figure 1 illustrates the pro-
gressive property of model. At any instant a one-step tran-
sition from small adenoma to clinical CRC is not allowed
but a multi-step transition is possible, although the likeli-
hood of transition from small to large adenoma, and from
large adenoma to pre-clinical CRC, within a year starts
low but increases with time. To build this feature into our
model, we allowed multiple-step transitions even within
one cycle to be possible although the chance is low. Thus,
although small adenoma has only a slim chance of pro-
gressing through large adenoma, preclinical early CRC,
and then to clinical early CRC chronologically within one
cycle but our model nevertheless allows for the possibil-
ity. Furthermore, since we wanted to simulate a screening
scenario, the initial state may be normal, adenoma, or
preclinical CRC with the corresponding prevalences at age
50 years. However, there are still lines emanating from the
root Markov node to clinical CRC, CRC death, and other
death, but the probabilities of these states at the first cycle
(initial probabilities) are all zero.
Description of screening strategies
The "No Screening" strategy follows the disease natural
history. The screening procedures for other screening
strategies are shown in Figure 2. In stool DNA screening
strategies, subjects in the normal, adenoma, or preclinical
phase of CRC states will be offered screening but may, or
may not, take up stool DNA testing. After modeling the
uptake of stool DNA testing, the number of detected cases
of adenoma or preclinical CRC is determined by the sen-
sitivity and specificity. A proportion of subjects with pos-
itive stool DNA test results will undergo further
examination (colonoscopy to detect adenoma and pre-
clinical CRC) as fixed by the compliance rate. The compli-
cations of perforation and death due to colonoscopy are
also taken into account. Subjects who do not participate
in stool DNA testing, those with false negative results and
those who refuse diagnostic colonoscopy will return to
the disease natural history. Subjects detected with ade-
noma follow the surveillance procedure and screen-
detected cases of CRC follow the prognosis of CRC. The
Markov decision model for FOBT screening and sig-
moidoscopy screening is similar to that for screening by
stool DNA testing, but with different values for sensitivity
and specificity. With colonoscopy screening, the proce-
dure for positive results or the surveillance of adenoma is
also similar to that for stool DNA testing screening, except
that polyps detected with colonoscopy will be removed
directly.
Adenoma detected by screening will be removed by
polypectomy during first colonoscopy. In the light of the
American Cancer Society guidelines on screening and sur-
veillance for the early detection of colorectal adenomas
and cancer, the removal of adenoma will be followed up
with surveillance [9]. Any recurrence of neoplasm will fol-
low the disease natural history. Subjects with small ade-
Markov process for disease natural history and prognosis of colorectal cancer (CRC) Figure 1
Markov process for disease natural history and prognosis of colorectal cancer (CRC).* * The ovals represent Markov states; 
the solid arrows represent the direct transition between states, and the dotted arrows represent the transition toward com-
peting cause of death. Abbreviations: Small adenoma, adenoma smaller than 1 cm in size; large adenoma, adenoma larger than 1 
cm in size; early CRC, Dukes' stage A and B colorectal cancer, late CRC, Dukes' stage C and D colorectal cancer; OCD, other 
cause of death.BMC Cancer 2006, 6:136 http://www.biomedcentral.com/1471-2407/6/136
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Table 1: Base-case estimates and ranges used in sensitivity analysis
Variable Base-Case Values (Range) Reference
The disease natural history and prognosis
Prevalence of colorectal neoplasm at age 50 years
Small adenoma 9.28% (4.64%–18.56%) 2–4, 17, 21*
Large adenoma 3.82% (0.96%–7.64%) 2–4, 17, 21*
Preclinical early CRC 0.12% (0.06%–0.24%) 2–4, 17, 21*
Preclinical late CRC 0.08% (0.04%–0.16%) 2–4, 17, 21*
Annual transition rates
Normal to small adenoma (λ1(t))
at age 50 years 0.00836 (0.00418–0.01672) 2–4, 17, 21*
at age 55 years 0.00990 (0.00495–0.01980) 2–4, 17, 21*
at age 60 years 0.01156 (0.00578–0.02312) 2–4, 17, 21*
at age 65 years 0.01333 (0.00667–0.02666) 2–4, 17, 21*
at age 70 years 0.01521 (0.00761–0.03042) 2–4, 17, 21*
Small adenoma to large adenoma (λ2) 0.0346 (0.0173–0.0692) 2–4, 17, 21*
Large adenoma to preclinical early CRC (λ3) 0.0215 (0.0108–0.0430) 2–4, 17, 21*
Preclinical early CRC to preclinical late CRC (λ4) 0.3697 (0.2678–0.4715) 22
Preclinical early CRC to clinical early CRC (λ5) 0.2382 (0.2055–0.2709) 22
Preclinical late CRC to clinical late CRC (λ6) 0.4852 (0.3207–0.6498) 22
Early CRC to CRC death (λ7) 0.0302 (0.0151–0.0604) 2–4, 23
Late CRC to CRC death (λ8) 0.2099 (0.1050–0.4198) 2–4, 23
Screening and diagnostic test characteristics
Flexible sigmoidoscopy reach 50 (50–60) 25
Sensitivity, %
Stool DNA testing
Small adenoma 8 (5–75) 16
Large adenoma 15 (12–82) 10–12, 16
Preclinical CRC 52 (50–100) 10–12, 16
FOBT
Small adenoma 5 (2–10) 26–31
Large adenoma 10 (5–20) 26–31
Preclinical CRC 50 (13–90) 26–31
Flexible sigmoidoscopy and colonoscopy
Small adenoma 78.5 (73–84) 25
Large adenoma 85 (85–90) 25
Preclinical CRC 95 (90–100) 25, 32–38
Specificity, %
Stool DNA testing 94 (89–100) 10–12, 16
FOBT 97.5 (95–100) 2–4
Flexible sigmoidoscopy 94 (92–96) 25
Colonoscopy 98 (96–100) 25
Complication of colonoscopy
Perforation rate, % 0.2 (0.07–0.85) 39–40
Death rate due to perforation, per 100,000 10 (0–50) 39–40
Costs, $BMC Cancer 2006, 6:136 http://www.biomedcentral.com/1471-2407/6/136
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noma will receive colonoscopy after 5 years. Then, if
normal, they return to the normal state in the natural his-
tory and are screened according to the standard screening
strategies. A similar procedure is applied to subjects found
to have a large adenoma. They will receive colonoscopy
three years after the initial polypectomy and, assuming no
adenoma after two repeated colonoscopies, return to the
normal state in the natural history mode.
Base-case estimates
Base-case estimates of the disease natural history and
prognosis, screening and diagnostic test characteristics,
and costs for cost-effectiveness analysis were abstracted
from published literature and are listed in Table 1. Note
that the base-case estimates of sensitivity and specificity of
stool DNA testing were obtained from the Imperiale et al
[16] study that has been so far the only one considering
average risk asymptomatic subjects aged 50 years.
Transition parameters
Parameters for the disease natural history and prognosis
were derived from previous studies [2-4,17,22-24]. The
transition rates between various invasive carcinoma states,
λ4-λ6, were obtained from selective screening for CRC, the
Taiwan Multicenter Cancer Screening (TAMCAS) Project
[21]. Regarding prevalence rate of adenoma, the preva-
lence estimates for large adenoma in previous randomised
trials [2-4] and the cumulative risk of 35% at 20 years of
carcinoma developing from large adenoma [21] coupled
with the age-specific CRC incidence rates in Taiwan in
2000 [17], were used to project the age-specific preclinical
incidence of small adenoma, λ1(t) (assuming a Weibull
distribution), the transition rate from small to large ade-
noma, λ2, (assuming an exponential distribution) and the
transition rate from large adenoma to preclinical early
CRC [22], λ3 (assuming an exponential distribution). The
estimated age-specific preclinical incidences of small ade-
noma are shown in Table 1. Assuming survival time fol-
lows exponential distribution, the parameters for survival
with clinical CRC, λ7 and λ8, were derived from the sur-
vival probabilities for each stage of CRC [23] after weight-
ing the distribution of CRC stage among the control
groups according to previous studies [2-4]. Age-specific
mortality, μ(t), for other cause of death, refer to Taiwan's
vital statistics in 2002 [24]. The prevalence of colorectal
neoplasm at age 50 years was obtained by converting the
transition rates mentioned above and are shown in Table
1.
Test characteristics
The estimated parameters for test characteristics such as
sensitivity, specificity, and complication with colonos-
copy were derived from previous studies [2-4], [10-
14,16,25-40]. This sensitivity is allowed to vary with state.
The base-case estimates of sensitivity of stool DNA testing
were 8% for small adenoma, 15% for large adenoma and
52% for invasive cancer [16]. The base-case estimate of
specificity of stool DNA testing was 94% [16].
Attendance and compliance
In the light of reality from previous study, as compliance
rates and referral rate vary with screening tools, 60% of
compliance rate was assumed for FOBT referring to evi-
dence from several randomised trials [1-4], and 40% of
compliance rate was assumed for sigmoidoscopy and
colonoscopy in the light of reality from previous studies
[41,42]. The compliance with stool DNA testing was
assumed to be the same with FOBT. The referral rate to
Screening
Stool DNA testing 44.1 (22.1–88.2) Expert opinion
FOBT 0.6 (0.3–1.2) BNHI
Flexible sigmoidoscopy 35.3 (17.6–70.6) BNHI
Colonoscopy 66.2 (33.1–161.8) BNHI
Treatment and confirmation
Pathological examination 20.6 (10.3–41.2) BNHI
Biopsy 13.2 (6.6–26.5) BNHI
Colonoscopy 66.2 (33.1–161.8) BNHI
Polypectomy 42.4 (21.2–84.7) BNHI
Initial cost for early CRC 3117.6 (1558.8–6235.3) BNHI
Initial cost for late CRC 7705.9 (3852.9–15411.8) BNHI
Continuing cost for CRC 176.5 (88.2–352.9) BNHI
Terminal Care for CRC 7647.1 (3823.5–15294.1) BNHI
Complication cost for perforation 1617.6 (808.8–3235.3) BNHI
Complication cost for death 2735.3 (1367.6–5470.6) BNHI
Discount rate, % 3 (0–7)
Abbreviations: CRC, colorectal cancer; FOBT, fecal occult blood testing; BNHI, Bureau of National Health Insurance.
* The estimates were obtained and re-estimated by combining several data sources [2–4, 17, 21].
Table 1: Base-case estimates and ranges used in sensitivity analysis (Continued)BMC Cancer 2006, 6:136 http://www.biomedcentral.com/1471-2407/6/136
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diagnostic colonoscopy after positive findings with
screening was assumed to be 85% according to several
randomised trials [1-4].
Costs
Costs are expressed in US dollars (1 US dollar = 34 New
Taiwanese dolloar, exchange rate on the basis of the year
2004). As the cost-effectiveness analysis is carried out
from the third-party payer perspective only direct costs
were calculated in this study, including those relating to
the screening itself, treatment and diagnostic tests (ade-
noma and CRC only), complications from colonoscopy
and surveillance (adenoma only). All estimates of cost
refer to the price mandated by the Bureau of National
Health Insurance in 2004 or expert opinion. Screening
costs, except for stool DNA testing, are based on Medicare
Payments by the Bureau of National Health Insurance.
The cost of stool DNA testing was estimated by experts
after considering the cost of the required laboratory man-
power and relevant materials in Taiwan. Treatment and
confirmation costs, which relate to polypectomy, biopsy,
and pathological examination, were acquired from Medi-
care Payments by the Bureau of National Health Insur-
ance. The lifetime costs for CRC encompass the initial
costs regarding surgery, chemotherapy and radiotherapy,
the continuing costs of follow-up after potentially curative
therapy, and the eventual cost of terminal care. For the
purposes of this costing, expenditure on terminal care is
only included for those who (in our models) die from
CRC. For early CRC, the initial cost includes only surgery.
All future costs and life-years were discounted to the
present value at an annual rate of 3%.
Structure of decision tree model Figure 2
Structure of decision tree model.* * At the beginning of the first Markov cycle, all the probabilities of being in clinical early 
CRC, clinical late CRC, surveillance for small adenoma, surveillance for large adenoma, screen-detected early CRC, screen-
detected late CRC, CRC death, complication death, and other death are zero. Ovals are the chance nodes governed by the 
probability related to compliance rate, sensitivity, specificity, and referral rate. : Markov cycle. Abbreviations: CRC, color-
ectal cancer; DNA3, stool DNA testing every 3 years; DNA5, stool DNA testing every 5 years; DNA10, stool DNA testing 
every 10 years; FOBT1, fecal occult blood testing every year; SIGM5, sigmoidoscopy every 5 years; COLO10, colonoscopy 
every 10 years; Small adenoma, adenoma smaller than 1 cm in size; large adenoma, adenoma larger than 1 cm in size; early 
CRC, Dukes' stage A and B colorectal cancer; late CRC, Dukes' stage C and D colorectal cancer.
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Cost-effectiveness analysis
Incremental cost-effectiveness ratio
The comparisons between the "No Screening" and other
screening strategies were first evaluated on the basis of the
incremental cost-effectiveness ratio (ICER), which is
defined as the difference between the two screening
groups in terms of cost divided by the difference between
them in terms of effectiveness, i.e. the extra cost required
to save additional life-years. The ICERs for stool DNA test-
ing as compared to the other screening strategies were also
calculated. A cost of $13,000 per life-year saved, which is
approximately equivalent to per capita GNP in Taiwan in
2003, was chosen as the ceiling ratio for assessing whether
the program is cost-effective.
Sensitivity analysis
As several parameters are uncertain, including the preva-
lence of colorectal neoplasm at age 50 years, transition
rates, sensitivity and specificity of screening tool, cost of
per unit of stool DNA testing, compliance to screening
tool, referral rate to diagnostic colonoscopy, and cost of
treatment, a series of one-way sensitivity analyses were
performed to assess the influence of changing these
parameters on the ICER results. The ranges of variables
used in sensitivity analysis are shown in Table 1. Note that
improved or worsened sensitivity for small adenoma may
lead to changes in sensitivity further down the line, for
example, with regard to large adenoma. In this study we
assume that any changes in sensitivity to detect small ade-
noma are paralleled by an equivalent change in sensitivity
to detect large adenoma. Similar assumptions were made
regarding early and late invasive cancer.
Furthermore, as the previous studies have rather dissimi-
lar estimates for sensitivity and specificity of stool DNA
testing, sensitivity analyses were emphasized on the dem-
onstration of the influence of sensitivity and specificity
regarding stool DNA testing using the moderate case sce-
nario in which the sensitivities and specificity were
obtained from the meta-analysis based on previous stud-
ies [10-13,16], and the best case scenario, in which the
sensitivities were mainly based on the estimates from Ahl-
quist study [10] except that the sensitivity of small ade-
noma was also based on Imperiale study [16]. The
sensitivity of stool DNA testing for small adenoma, large
adenoma, and colorectal cancer, and the specificity are
8%, 18%, 85%, and 94% in the moderate case scenario.
The corresponding estimates in the best case scenario are
8%, 82%, 91%, and 93%, respectively.
As the compliance varies with the screening tool and
county, it is important to explore the influence of compli-
ance rate to each screening tool. Therefore, a range of val-
ues between 10% and 100% were used in the sensitivity
analysis to assess the impact of compliance with each
screening tool.
Results
The model predicted that the cumulative incidence of
CRC in ages 50 to 75 years, would be 36 per 1,000, which
is close to the observed cumulative incidence of CRC in
Taiwan (Taiwan Cancer Registry, 37 per 1,000) (Figure 3)
[17].
Base-case analysis
Table 2 shows the simulated number of total cases of
CRC, predicted number of CRC deaths, and perforation
related deaths, in a cohort of 100,000 persons sub-classi-
fied by screening strategy, given 60% of compliance rate
with FOBT1, DNA3, DNA5, and DNA10, 40% of compli-
ance rate with SIGM5 and COLO10, and 85% of referral
rate after a positive screening results. COLO10 and FOBT1
have similar effect on CRC mortality with 39% reduction
which is the greatest one among all the screening strate-
gies. DNA10 is the least effective screening strategy. The
reductions in incidence with screening, compared to no
screening, were very similar. However, stool DNA testing
and FOBT reduces CRC incidence by far less than CRC
mortality because of its poor sensitivity for adenoma.
The ICERs for other screening strategies, as compared to
"No Screening" are also listed in Table 2. In this setting,
COLO10 and FOBT1 are both the most cost-effective strat-
egies which are more effective and less costly than No
Screening. The incremental costs for DNA3, DNA5, and
DNA10, respectively, were calculated as $9,794, $9,335,
and $7,717 per life-year saved, which is much less cost-
effective than other screening strategies. Stool DNA testing
Comparison of observed and predicted cumulative colorectal  cancer incidence Figure 3
Comparison of observed and predicted cumulative colorectal 
cancer incidence.
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strategies were out-performed by all the other screening
strategies. However, all screening strategies (including
stool DNA testing) are cost-effective compared to No
Screening.
Sensitivity analysis
For identifying the influential parameters on ICER for
stool DNA testing compared with No Screening, a series of
sensitivity analyses were carried out (see Table 3). When
the cost per stool DNA test is larger than $57.1, referral
rate with diagnostic colonoscopy is lower than 67%, and
prevalence of large adenoma at age 50 years is smaller
than 2.42%, DNA3 was not cost-effective compared to
$13,000 per life-year saved. Similar ICER estimates were
obtained for comparisons between DNA5, DNA10, and No
Screening. Besides, the discount rate also has great influ-
Table 3: One-way sensitivity analysis.
Variables Base- Case
Values
Sensitivity
Analysis Values
Incremental Cost($)/Life-Year Saved
DNA3 DNA5 DNA10
Range Threshold Range Threshold Range Threshold
Base-case 9,794 9,335 7,717
Sensitivity of DNA for 
small/large adenoma
8%/15% 75%/82% 11,546 – 1,742 -- 11,122 – 1,030 -- 9,369 – 269 --
Sensitivity of DNA for 
preclinical CRC
52% 50%–100% 9,921 – 7,078 -- 9,454 – 6,752 -- 7,817 – 5,528 --
Cost per DNA $44.1 $22.1-$88.1 4,344 – 2,0706 $57.1 4,194 – 19,628 $60.0 3,271 – 1,6618 $70.3
Compliance with DNA 60% 10%–100% 9,070 – 10,423 -- 9,047 – 9,582 -- 7,630 – 7,787 --
Referral rate to 
diagnostic colonoscopy
85% 10%–100% 85,266 – 8,294 67% 83,868 – 7,843 63% 73,826 – 6,396 53%
Prevalence of large 
adenoma
3.82% 0.96%–7.64% 18,969 – 5,387 2.42% 18,184 – 5,114 2.23% 15,657 – 4,042 1.58%
Discount rate 3% 0%–7% 6,938 – 15,674 -- 6,738 – 14,864 -- 5,107 – 13,281 --
DNA3, stool DNA testing every 3 years; DNA5, stool DNA testing every 5 years; DNA10, stool DNA testing every 10 years; FOBT1, fecal occult 
blood testing every two year; SIGM5, sigmoidoscopy every 5 years; COLO10, colonoscopy every 10 years.
Table 2: Simulated results for screening strategies to prevent CRC*
Variable Screening Strategy
No Screening DNA3 DNA5 DNA10 FOBT1 SIGM5 COLO10
Total cases of CRC, n 2,917 2,435 2,654 2,710 2,129 2,253 1,780
CRC deaths, n 1,729 1,345 1,467 1,574 1,059 1,328 1,077
Perforation deaths, n 0 3 2 1 5 3 12
Reduction in CRC incidence, % 0 17 9 7 27 23 39
Reduction in CRC mortality, % 0 22 15 9 39 23 39
Life expectancy, year 15.7337 15.7476 15.7434 15.7400 15.7584 15.7477 15.7590
Total costs, thousand $ 22,022 35,637 31,077 26,856 19,824 24,909 21,843
Incremental life-year saved, year 0 1,390 970 626 2,464 1,383 2,530
Incremental cost, thousand $ 0 13,615 9,054 4,834 -2,198 2,887 -180
Incremental cost ($)/life-years saved compared with no 
screening
0 9,794 9,335 7,717 Dominant‡ 2,087 Dominant‡
Incremental cost ($)/life-years saved:
DNA3vs. other screening strategies -- -- -- -- Dominant† Dominant† Dominant†
DNA5 vs. other screening strategies -- -- -- -- Dominant† Dominant† Dominant†
DNA10 vs. other screening strategies -- -- -- -- Dominant† Dominant† Dominant†
Abbreviations: CRC, colorectal cancer; DNA3, stool DNA testing every 3 years; DNA5, stool DNA testing every 5 years; DNA10, stool DNA 
testing every 10 years; FOBT1, fecal occult blood testing every two year; SIGM5, sigmoidoscopy every 5 years; COLO10, colonoscopy every 10 
years.
* Values obtain from a cohort of 100,000 persons 50 years of age who were followed for 25 years.
† The other screening strategy is more effective and less costly than stool DNA testing strategy.
‡ The screening is more effective and less costly than No Screening.BMC Cancer 2006, 6:136 http://www.biomedcentral.com/1471-2407/6/136
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ence on the ICER of DNA3, DNA5, and DNA10 compared
with No Screening. When the discount rate increases, the
ICER of DNA3, DNA5, and DNA10 increase rapidly.
Since the estimates for sensitivity of stool DNA testing
vary from study to study, scenario analyses were con-
ducted to assess the impact of sensitivity of stool DNA
testing strategy (see Figure 4). In the moderate case sce-
nario in which the sensitivities and specificity were mainly
derived from the meta-analysis based on previous studies
[10-13,16], the estimated ICER were similar to the base-
case estimates (worst case scenario) which based on Impe-
riale study [16] (see two bottom curves in Figure 4). The
ICER for DNA3, DNA5, and DNA10 are much less cost-
effective than other screening strategies but still remained
cost-effective compared to No Screening. Assuming the
best case scenario in which the sensitivities were mainly
based on the estimates from Ahlquist study [10], stool
DNA testing strategies became comparable with other
screening strategies, and the incremental costs for DNA3,
DNA5, and DNA10, respectively, were calculated as
$3,825, $3,036, and $2,194 per life-year saved. DNA3 and
DNA5 saved more lives than FOBT1 and COLO10, but with
high cost
The results of sensitivity analysis regarding compliance
rate to each screening tool are illustrated in Figure 5. The
effectiveness of 100% compliance to FOBT1 is approxi-
mately equivalent to COLO10 with 60% compliance rate.
SIGM5 with 80% compliance is as effective as FOBT1 with
60% compliance and COLO10 with 40% compliance but
with higher cost. DNA3  with 100% compliance has
approximately equivalent effectiveness compared with
FOBT1 with 50% compliance and COLO10 with 30% com-
pliance but with much higher cost. The corresponding fig-
ures were FOBT1 with 30% compliance and COLO10 with
20% compliance for DNA5, and were FOBT1 with 20%
compliance and COLO10  with 15% compliance for
DNA10.
Discussion
The present study is a formal economic evaluation of
DNA3, DNA5, and DNA10 in relation to several alterna-
tives (No Screening, FOBT1, SIGM5, and COLO10) using
Taiwanese data on colorectal cancer incidence and disease
natural history, sub-classified by adenoma size and
Dukes' stage in invasive carcinoma. The findings from this
study suggest that all of the screening strategies are reason-
ably cost-effective in relation to No Screening. However,
the stool DNA testing strategies were the least cost-effec-
tive. COLO10 and FOBT1 are the most cost-effective strat-
egy. Nevertheless, the feasibility of opting for
Sensitivity analysis regarding compliance to screening tool  (0.1, 0.2, 0.4, 0.6, 0.8, and 1.0) Figure 5
Sensitivity analysis regarding compliance to screening tool 
(0.1, 0.2, 0.4, 0.6, 0.8, and 1.0). Abbreviations: DNA3, stool 
DNA testing every 3 years; DNA5, stool DNA testing every 
5 years; DNA10, stool DNA testing every 10 years; FOBT1, 
fecal occult blood testing every year; SIGM5, sigmoidoscopy 
every 5 years; COLO10, colonoscopy every 10 years.
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Cost-effectiveness of CRC screening under different scenar- ios Figure 4
Cost-effectiveness of CRC screening under different scenar-
ios. Abbreviations: CRC, colorectal cancer; DNA3, DNA5, 
and DNA10, stool DNA testing every 3, 5, and 10 years, 
respectively; -W, under the worst case scenario (the same 
with the base-case estimates) in which the sensitivity of stool 
DNA testing for small adenoma, large adenoma, and colorec-
tal cancer, and the specificity are 8%, 15%, 52%, and 94% 
based on Imperiale et al study [10]; -M, under the moderate 
case scenario in which the corresponding estimates are 8%, 
18%, 85%, and 94% based on meta-analysis [10-13, 16]; -B, 
under the best case scenario in which the corresponding 
estimates are 8%, 82%, 91%, and 93% based on Ahlquist et al 
study [10]; FOBT1, fecal occult blood testing every year; 
SIGM5, sigmoidoscopy every 5 years; COLO10, colonoscopy 
every 10 years.
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colonoscopy as screening tool for average-risk groups may
be questionable due to the shortage of medical endo-
scopic manpower and the risk of perforation associated
with colonoscopy. Stool DNA testing would be preferable
to the other screening strategies if the sensitivity for both
adenoma and CRC were high enough, as seen in the best
case scenario of sensitivity analysis from the Ahlquist
study [10], and if the cost of the test could be lowered
through economies of scale like the example of hepatitis
B vaccination the price of which has dramatically fallen
due to the advent of universal program in 1990s [43].
However, the interpretation of the finding in the best case
scenario should be taken with great caution because sub-
jects enrolled in Ahlquist study [10] was based on clinical
series patients rather than asymptomatic subjects from
average-risk population [16].
It should be noted that our focus on this study was to
assess whether stool DNA testing was cost-effective pro-
vided stool DNA testing can be used as another alternative
choice for population-based screening. The incremental
cost-effectiveness analysis by pairwise comparison across
different screening tools (i.e. colonoscopy vs. stool DNA
testing) was therefore not attempted.
Although stool DNA testing has been proposed in recent
years its application to mass screening for colorectal can-
cer has not been evaluated. The major deterrent has been
doubt over the performance of test. Previous studies show
a wide range of sensitivities for stool DNA testing, ranging
from 15% to 82% for large adenoma and from 50% to
100% for invasive CRC [10-13,16]. This variation may
often be attributed to differences in the way asymptomatic
subjects or symptomatic cases were selected, although this
was not the case in the Imperiale et al study [16]. The larg-
est study to focus on asymptomatic subjects (the major
target of mass screening) showed 8% sensitivity for small
adenoma, 15% for large adenoma and 52% for invasive
CRC [16]. False negative cases, as a result of low sensitiv-
ity, may lower its effectiveness as a tool for screening
asymptomatic subjects in the general population. How-
ever, to integrate state-of-world information obtained
form previous studies, we used the meta-analysis to
obtain the estimate by taking all previous studies into
account as the moderate case scenario. However, the esti-
mate of sensitivity of adenoma has been largely affected
by the Imperial study [16] because it is the largest study up
to date on screening for colorectal cancer with stool DNA
testing. The estimate based on meta-analysis for the sensi-
tivity of cancer has been estimated as 85% by weighting
the inverse variance of each study.
It could be argued that stool DNA testing screening is to
be more expensive than other screening tools. This may be
true at the inception of screening strategy but with wide-
spread use, we might reasonably expect savings due to
economies of scale. Genetic epidemiology is still in its
infancy but the development of genetic chip technology
and DNA testing advances may soon facilitate the devel-
opment of simple commercial stool DNA testing kits,
which would be considerably cheaper.
Very few studies have addressed the economic aspects of
adopting stool DNA testing as screening tool for use in the
general population. Only Song et al [44] and Leshno et al
[45] have performed a study on cost-effectiveness, com-
paring fecal DNA testing with conventional CRC screen-
ing. The parameters in the former study are based on
Western countries with a high prevalence of CRC, and the
parameters in the latter study are based on Israel which
also has a high incidence rate of CRC [46]. To the best of
our knowledge, no similar studies on stool DNA testing
have been conducted in countries with low or intermedi-
ate incidence of CRC. Furthermore, the base-case esti-
mates of sensitivity and specificity for stool DNA testing
may vary across studies. The sensitivity and the specificity
used in Leshno study are 70%, 82%, 91%, and 90% for
small adenoma, large adenoma, preclinical CRC, and spe-
cificity, respectively, which were similar to our best case
scenario, and only annual stool DNA testing has been
considered [45]. The corresponding estimates in Song
study are 40%, 40%, 65%, and 95%, respectively [44].
Compared with the two previous studies [44,45], the
base-case estimates in our study are the most conservative
ones which only base on the population-based study [16].
However, despite the diversified parameter regarding sen-
sitivity and specificity, our findings that stool DNA testing
is cost-effective compared to No Screening but inferior to
conventional screening methods such as FOBT and colon-
oscopy are consistent with Song et al's and Leshno et al's
findings [44,45].
The reported ICERs in this study are much lower than that
reported in other cost-effectiveness analysis [44,47,48].
This discrepancy can be explained by the low cost of
screening tool, and other relevant cost for CRC treatment
and diagnosis used in this study which represents the real-
ity in Taiwan. When we used the cost based on the West-
ern country as our base-case parameters [44], given perfect
compliance and perfect referral rate as assumed in the pre-
vious studies, the ICERs are comparable with the previous
studies [44,47,48]. The ICER for FOBT1, SIGM5, and
COLO10 compared with No Screening are estimated as
$2,376, $20,206 and $13,831 per life-year saved, respec-
tively. However, all the stool DNA testing strategies are
not cost-effective and the ICERs inflate to approximately
$115,000 per life-year saved for DNA10 compared with No
Screening.BMC Cancer 2006, 6:136 http://www.biomedcentral.com/1471-2407/6/136
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The compliance may have large influence on the cost and
the effectiveness of a screening program. Nevertheless, the
compliance may vary widely by different screening tool
and population [49], therefore, the decision should be
made by the preference of each population. Figure 5 has
shown the influence of different compliance level of each
screening tool on the cost-effectiveness which allows the
assessment for various compliance rates to each screening
tool. For example, for a population with the compliance
of 40% with FOBT1 and of 20% with SIGM5 and COLO10,
FOBT1would save more lives and less costly than all the
other screening strategies. However, for a population with
the compliance of 50% with FOBT1 and of 40% with
SIGM5 and COLO10, COLO10 would have more life-year
gained than FOBT1 but with higher cost.
As far as the validity of our simulation model is con-
cerned, our results obviously depend on the parameters
chosen for the natural history part of the model. Three
findings lead us to believe that our simulated model is
adequate. Firstly, the predicted cumulative incidence of
CRC in our study, 34 per 1,000, is close to the observed
one, 37 per 1,000 [17]. Secondly, our sensitivity analyses
demonstrates that changes to the upper and lower bounds
of our estimates do not lead to substantial changes in our
results. Thirdly, to check whether our simulated results on
the effectiveness of FOBT test are consistent with those
reported in several randomized trials [1-4], we applied
60% (56.5%~67%) compliance rate of FOBT and 85%
referral rate to diagnostic colonoscopy and identical tran-
sition parameters based on base-case parameters, and
shortened follow-up year to 10 years as seen in rand-
omized trial, the predicted mortality reduction for annual
FOBT screening and biennial FOBT screening is 20% and
13%, respectively, the latter of which is close to the find-
ings from several randomised trials with two-yearly inter-
screening interval, indicating 16%, 21%, and 15% mortal-
ity reduction conducted in Burgundy (France) [4], Funen
(Denmark) [3], and Nottingham (UK) [2], respectively.
For the incidence, the incidence ratio was estimated as
0.80 (annual FOBT) after follow-up for 18 years, which
was close to the estimate reported in randomized trial [1].
Since this study was conducted from a third-party payer
perspective, we therefore adopted the price mandated by
the Bureau of National Health Insurance (95% popula-
tion covered) as the cost and only direct costs were
included. However, indirect costs such as production loss
due to attending to screening or due to disease should be
considered from the societal viewpoint. This could be the
subject of future studies.
Our study has, however, one limitation as our proposed
model assumes an adenoma to carcinoma sequence,
which accounts for the majority of CRCs. Non-polypoid
cases are not taken into account. However, as only a frac-
tion of CRCs are non-polypoid and the cost-effectiveness
analysis addresses the relative comparisons across screen-
ing strategies, the incorporation of the occurrence of non-
polypoid tissue is unlikely to substantially affect the
results.
Conclusion
In conclusion, an economic evaluation of CRC screening
with stool DNA testing was performed in a country with
an intermediate incidence of CRC. Our results suggest that
stool DNA testing is less cost-effective than other currently
recommended strategies for population-based average-
risk subjects.
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